Accessibility Menu
Scinai Immunotherapeutics Stock Quote

Scinai Immunotherapeutics (NASDAQ: BVXV)

$1.42
(2.2%)
+0.03
Price as of October 23, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$1.42
Daily Change
(2.2%) +$0.03
Day's Range
$1.35 - $1.47
Previous Close
$1.42
Open
$1.36
Beta
0.84
Volume
53,118
Average Volume
1,068,478
Market Cap
1.2M
Market Cap / Employee
$1.39M
52wk Range
$1.2 - $6.18
Revenue
-
Gross Margin
-3.39%
Dividend Yield
N/A
EPS
$4.91
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Scinai Immunotherapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
BVXV-61.6%-99.73%-69.42%-100%
S&P+14.5%+93.32%+14.09%+219%

Scinai Immunotherapeutics Company Info

BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.19M-32.5%
Gross Profit-$0.67M-690.6%
Gross Margin-323.30%0.0%
Market Cap$1.94M50.7%
Market Cap / Employee$0.06M0.0%
Employees310.0%
Net Income-$2.63M-13.7%
EBITDA-$1.78M-0.6%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$0.99M-69.2%
Accounts Receivable$0.08M0.0%
Inventory00.0%

Liabilities

Q4 2024YOY Change
Long Term Debt$1.66M-91.8%
Short Term Debt$0.42M7.1%

Ratios

Q4 2024YOY Change
Return On Assets24.20%0.0%
Return On Invested Capital-4.56%40.6%

Cash Flow

Q4 2024YOY Change
Free Cash Flow-$1.09M29.1%
Operating Free Cash Flow-$1.09M16.2%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Earnings11.301.220.460.46-
Price to Book-0.400.650.530.45-252.33%
Price to Sales8.236.454.33-
Price to Tangible Book Value-0.400.650.530.45-252.33%
Enterprise Value to EBITDA-9.54-14.22-4.46-4.76-54.04%
Return on Equity99.4%138.4%-
Total Debt$20.63M$20.82M$1.23M$2.09M-89.85%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.